Jump to main content
Jump to site search

Issue 47, 2020
Previous Article Next Article

Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy

Author affiliations

Abstract

Chemotherapy for non-small-cell lung cancer (NSCLC) treatment has been employed over the past 20 years. However, poor water-solubility, low bioavailability and less drug accumulation of chemotherapeutic drugs restrict its antitumor activities in clinic. DNA nanostructures are proposed as drug carriers due to their intrinsic biocompatibility and programmability. In this work, we demonstrate a novel DNA nanocarrier grafted with erlotinib as an effective drug delivery system (DDS) for anti-cancer treatment. Specifically, erlotinib (Er), a hydrophobic small molecule drug targeting the epidermal growth factor receptor (EGFR), is covalently conjugated with azide (N3) modified DNA strands and subsequently self-assembled on spatially programmable erlotinib-grafted 6 × 6 × 64 nt DNA nanostructures. Thus, Er was successfully grafted on DNA carriers and transformed into a hydrophilic formulation. The antitumor efficacy was evaluated both in vitro and in vivo, and enhanced cytotoxicity toward A549 cells and the marked inhibition of tumor growth for non-small-cell lung cancer (NSCLC) were observed.

Graphical abstract: Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy

Back to tab navigation

Supplementary files

Article information


Submitted
28 Sep 2020
Accepted
12 Nov 2020
First published
17 Nov 2020

Nanoscale, 2020,12, 23953-23958
Article type
Communication

Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy

Y. Wang, J. Cheng, D. Zhao, Y. Liu, T. Luo, Y. Zhong, F. Mo, X. Kong and J. Song, Nanoscale, 2020, 12, 23953
DOI: 10.1039/D0NR06945K

Social activity

Search articles by author

Spotlight

Advertisements